Akston Biosciences Stock
Akston Biosciences Corporation leverages its novel fusion protein platform to develop and manufacture new classes of biologics.
Sign up today and learn more about Akston Biosciences Stock
Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.
About Akston Biosciences Stock
Akston Biosciences Corporation leverages its novel fusion protein platform to develop and manufacture new classes of biologics, including vaccines, ultra-long-acting insulins, and autoimmune disease therapies. It was founded in 2011 and headquartered in Beverly, Massachusetts.
Funding History
| February 2013 | $700K |
|---|---|
| May 2015 | $1.6M |
| September 2015 | $250K |
| August 2016 | $3.4M |
| February 2017 | $998K |
| February 2018 | $999K |
| May 2018 | $3.9M |
| June 2019 | $979K |
| April 2020 | $7.8M |
| May 2020 | $924K |
| June 2021 | $19.9M |
| April 2022 | $5.2M |
Management
Co-founder, President, and CEO
Todd C. Zion
Press
patents - Apr, 14 2024
Ultra-long acting insulin-fc fusion proteinpatents - Apr, 14 2024
Antigen specific immunotherapy for covid-19 fusion proteins and methods of usepatents - Apr, 14 2024
Ultra-long acting insulin-fc fusion proteins and methods of usepatents - Apr, 14 2024
Ultra-long acting insulin-fc fusion proteins and methods of usepatents - Apr, 14 2024
Insulin-fc fusion proteins and methods of use to treat cancerEquityZen Recognized As:
